针对EGFR Exon 20插入 (Ex20ins) 突变的结构机制和抑制剂
Hao Chen1, Shiliang Hu1, Adam V Patterson2,3
1International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Discovery of Chinese Ministry of Education (MOE), School of Pharmacy, Jinan University, 855 Xingye Avenue, Guangzhou 510632, China.
新疗法针对非小细胞肺癌 (NSCLC) 的表皮生长因子受体 (EGFR) 插入外20突变 (Ex20ins). 本研究分析了耐药性机制和抑制剂结合,以改善下一代EGFR Ex20ins治疗方法.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- 针对表皮生长因子受体 (EGFR) 的向治疗对于EGFR突变非小细胞肺癌 (NSCLC) 至关重要.
- 许多患有EGFR外显子20插入 (Ex20ins) 突变的患者对现有的EGFR抑制剂反应不佳.
- 莫博塞蒂尼布代表了最近的进步,为EGFR Ex20ins突变提供了向治疗.
研究的目的:
- 系统地总结 EGFR Ex20ins 突变的耐药性背后的结构机制.
- 描述针对EGFR Ex20ins突变的抑制剂的结合方式.
- 为开发下一代EGFR Ex20ins抑制剂提供见解.
主要方法:
- 在EGFR Ex20ins突变中对连接体结合的结构机制的分析.
- 审查与EGFR Ex20ins突变相关的耐药性机制.
- 关于EGFR Ex20ins突变抑制剂的最近发展情况的摘要.
主要成果:
- 确定导致EGFR Ex20ins NSCLC反应不佳的关键结构因素.
- 抑制剂如何与EGFR Ex20ins突变结合的特征.
- 目前治疗策略及其局限性的概述.
结论:
- 了解结构机制对于克服EGFR Ex20ins NSCLC中的抵抗至关重要.
- 需要进一步的研究来设计更有效的抑制剂,以应对这种具有挑战性的突变.
- 这一观点有助于合理设计未来EGFR Ex20ins的向疗法.
更多相关视频
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
相关概念视频
Mitogens and the Cell Cycle
Targeted Cancer Therapies
There are several types of targeted therapies against...
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Inhibition of Cdk Activity
Receptor Tyrosine Kinases
Enzyme-linked Receptors
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
